Akeso (09926) plans to repurchase shares with a maximum of HK$200 million, and the executive directors and senior management plan to increase their holdings.

date
12:06 11/06/2026
avatar
GMT Eight
Kangfang Bioscience (09926) announced that on June 11, 2026, the Board of Directors approved the use of up to 200 million Hong Kong dollars to repurchase the company's ordinary shares (shares) in the open market. The repurchase of shares will be executed by the trustees of the company's restricted share unit plan for 2021. The Board of Directors believes that the current trading price of the shares does not reflect the company's intrinsic value and business prospects, and now is a good opportunity to buy back shares. The proposed share repurchase demonstrates the Board of Directors' and management's confidence in the company's business outlook and prospects, and will benefit the company, creating value for shareholders. The proposed share repurchase will be funded by the company's existing available cash resources.
AKESO (09926) Announcement: On June 11, 2026, the Board of Directors of the Company approved the use of up to HK$200 million to buy the Company's ordinary shares on the open market. The purchase of shares will be executed by the trustee of the Company's 2021 Restricted Share Unit Plan. The Board believes that the current trading price of the shares does not reflect the Company's intrinsic value and business prospects, and now is a good opportunity to buy back shares. The proposed share buyback demonstrates the Board and management's confidence in the Company's business outlook and prospects, benefiting the Company and creating value for shareholders. The proposed share buyback will be funded by the Company's existing available cash resources. The Board has also been informed that the Chairman, CEO, President, Executive Directors, and CFO of the Company ("relevant directors and senior management") plan to increase their shareholding in the Company by purchasing shares on the open market, with a total cap of HK$50 million, subject to compliance with listing rules and other applicable laws and regulations. The relevant directors and senior management have indicated that their planned increase in shareholding is based on their confidence in the Company's long-term investment value, strong research and development capabilities, and ability to drive continuous innovation, and will be funded by their own financial resources.